Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02405247 · ClinicalTrials.gov registry record
TAURAS - T790 AURA ScreenFailure SOC Registry Study
A clinical trial, sponsored by AstraZeneca.
- Terminated
- Registry status
- 400
- Enrollment target
NCT02405247 is a clinical trial that was terminated before completion, run by AstraZeneca. The registered enrollment target is 400 participants.
The verdict
NCT02405247 was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- 400 participants
- Enrollment target
Study Summary
The aim of this study is to evaluate clinical outcomes of 2nd line therapy in NSCLC patients without the T790M mutation, both independently and when compared indirectly with NSCLC patients with the T790M mutation in the T STAR non interventional study (D5160R00001). The patient population in the TAURAS study will consist of patients who fail screening for AURA3 (D5160C00003) due to a T790M mutation not detected using the central cobas® EGFR Mutation Test (Roche Molecular Systems).
Interventions
- OTHER Patient Reported Outcome (PRO)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2015-06 |
| Est. Completion | 2015-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02405247
The ClinicalTrials.gov registry entry for NCT02405247 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Patient Reported Outcome (PRO) is the first listed.
NCT02405247 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02405247 about?
NCT02405247 is a clinical study titled "TAURAS - T790 AURA ScreenFailure SOC Registry Study". The aim of this study is to evaluate clinical outcomes of 2nd line therapy in NSCLC patients without the T790M mutation, both independently and when compared indirectly with NSCLC patients with the T790M mutation in the T STAR non interventional study (D5160R00001). The patient population in the TA...
What is the current status of trial NCT02405247?
This trial is currently terminated. The enrollment target is 400 participants. The study started on 2015-06. Estimated completion is 2015-07.
What interventions are being tested in trial NCT02405247?
The interventions under investigation include: Patient Reported Outcome (PRO) (OTHER).
Who is sponsoring clinical trial NCT02405247?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.